Results of Therapy Including Omalizumab in Adolescents With Recurrent Urticaria: Retrospective Cohort Study
Relevance. Omalizumab is recommended for treatment of severe forms of recurrent urticaria in children since 12 years old. Though the Omalizumab efficiency and safety in children with recurrent urticaria have not been studied specifically.Objective. To estimate results of the therapy including Omaliz...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Paediatrician Publishers, LLC
2019-09-01
|
| Series: | Pediatričeskaâ Farmakologiâ |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/1739 |